Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Arjo AB (publ)
  6. News
  7. Summary
    ARJO B   SE0010468116

ARJO AB (PUBL)

(ARJO B)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Arjo : receives 510(k) clearance from US FDA for WoundExpress

09/06/2021 | 02:31am EDT

Arjo has received 510(k) clearance from the US Food and Drug Administration (FDA) for WoundExpress, an intermittent pneumatic compression (IPC) solution for accelerating healing of venous leg ulcers. The FDA clearance follows several recent studies showing that WoundExpress can significantly improve lower leg wound management.

"This is an important milestone for us and we see great potential in now bringing this innovative therapy to the US market as well", says Joacim Lindoff, President & CEO of Arjo. "Venous leg ulcers are a rapidly growing and costly problem for healthcare, with annual treatment costs estimated at approximately SEK 300 billion globally1, whereof the US market represents almost 50%. I am confident that WoundExpress will help solve the current issues both from a clinical and financial perspective", adds Joacim Lindoff.  

WoundExpress is expected to be launched in the US during Q1 2022.

A recently published research paper showed that WoundExpress, in combination with standard care, increased the probability of wound healing by 58% and improved the health-related quality of life for patients - with significant associated cost savings for healthcare.2

A randomized controlled trial (RCT) for wound care treatment is currently ongoing. Due to delays related to the Covid-19 pandemic, the RCT is expected to be finalized in Q2 2022.
 

About WoundExpress

Arjo's WoundExpress is an Intermittent Pneumatic Compression (IPC) system to manage lower leg wounds with a garment applied on the patient's thigh, uniquely placed away from the wound site to avoid painful pressure while increasing blood flow to the leg ulcer.

To date, WoundExpress has been introduced to the market in UK, Ireland, Sweden and Denmark - with very positive response. Commercialisation plans are currently under development for other major markets.

Read more about WoundExpress here: https://www.woundexpress.com/

1) NHS (2019); Wounds International (2015); Reeder et al. (2013); Guest et al. (2017); Corporate Development & Projects: Huntleigh Diagnostics
2) Guest et al, (2021)

For more information, please contact:                                                                                              

Kornelia Rasmussen, EVP Marketing Communications & Public Relations
Tel: +46(0)10 335 4810
E-mail: kornelia.rasmussen@arjo.com

Maria Nilsson, Investor Relations & Corporate Communications
Tel: +46 (0)10 335 4866
Email: maria.nilsson@arjo.com 

About Arjo

At Arjo, we believe that empowering movement within healthcare environments is essential to quality care. Our products and solutions are designed to promote a safe and dignified experience through patient handling, medical beds, personal hygiene, disinfection, diagnostics, and the prevention of pressure injuries and venous thromboembolism. With over 6,000 people worldwide and 60 years caring for patients and healthcare professionals, we are committed to driving healthier outcomes for people facing mobility challenges. www.arjo.com

https://news.cision.com/arjo/r/arjo-receives-510-k--clearance-from-us-fda-for-woundexpress,c3410326

https://mb.cision.com/Main/12208/3410326/1464620.pdf

https://news.cision.com/arjo/i/wound-express--20-home-flow-huntleigh-cmyk,c2950950

(c) 2021 Cision. All rights reserved., source Press Releases - English

All news about ARJO AB (PUBL)
10/04ARJO : announces date of 2021 Q3 report and conference call
AQ
09/15ARJO : Receives Innovative Technology Contract from Vizient for the ProvizioSEM Scanner
AQ
09/15Arjo Receives Innovative Technology Contract from Vizient for the Provizio SEM Scanner
CI
09/06ARJO : receives 510(k) clearance from US FDA for WoundExpress
AQ
09/06Arjo AB Receives 510(K) Clearance from US Food and Drug Administration for WoundExpress
CI
07/15Arjo Seeks Acquisitions
CI
07/15ARJO : interim report January-June 2021
AQ
07/15Arjo AB Publ Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
07/15ARJO AB (OM : ARJO B) acquired Rental operations of PAC Rentals.
CI
07/14ARJO : Research establishes clear health-economic argument for including WoundExpress as s..
AQ
More news
Financials
Sales 2021 9 144 M 1 064 M 1 064 M
Net income 2021 773 M 89,9 M 89,9 M
Net Debt 2021 4 873 M 567 M 567 M
P/E ratio 2021 46,0x
Yield 2021 0,90%
Capitalization 32 385 M 3 767 M 3 769 M
EV / Sales 2021 4,07x
EV / Sales 2022 3,79x
Nbr of Employees 6 000
Free-Float 74,8%
Chart ARJO AB (PUBL)
Duration : Period :
Arjo AB (publ) Technical Analysis Chart | ARJO B | SE0010468116 | MarketScreener
Technical analysis trends ARJO AB (PUBL)
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 118,90 SEK
Average target price 115,75 SEK
Spread / Average Target -2,65%
EPS Revisions
Managers and Directors
Karl Joacim Claesson Lindoff President, Chief Executive Officer & Director
Daniel Fńldt Chief Financial Officer
Johan Malmquist Chairman
Mikael Persson Executive Vice President-Supply Chain & Operations
Katarzyna Bobrow Executive VP-Quality & Regulatory Compliance
Sector and Competitors
1st jan.Capi. (M$)
ARJO AB (PUBL)89.18%3 767
ABBOTT LABORATORIES15.61%224 403
MEDTRONIC PLC5.48%166 288
BECTON, DICKINSON AND COMPANY-1.52%70 767
HOYA CORPORATION20.25%55 682
DEXCOM, INC.53.72%54 986